ClinicalTrialStartPulse: Phase 3, page 2 of 4
Records 51 to 200 of the 500 newest listed for this hub. Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
| Record | Phase | Conditions | Enrollment |
|---|---|---|---|
| DualityBio Inc. | Phase 3 | HER2-positive Breast Cancer | 228 |
| Merck Sharp & Dohme LLC | Phase 3 | Ovarian Cancer; Ovarian Neoplasms; Peritoneal Cancer; Fallopian Tube Cancer | 802 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 3 | Acute Ischemic Stroke AIS | 1092 |
| Janssen Research & Development, LLC | Phase 3 | Multiple Myeloma | 1000 |
| Kite, A Gilead Company | Phase 3 | Newly Diagnosed Multiple Myeloma | 750 |
| Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | 210 |
| Hoffmann-La Roche | Phase 3 | Neovascular Age-related Macular Degeneration (nAMD) | 451 |
| MedTrace Pharma A/S | Phase 3 | Coronary Artery Disease | 232 |
| Hoffmann-La Roche | Phase 3 | Primary IgA Nephropathy | 459 |
| BioNTech SE | Phase 3 | Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer | 358 |
| Eli Lilly and Company | Phase 3 | Obesity; Overweight; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 3000 |
| Biohaven Therapeutics Ltd. | Phase 3 | Graves' Disease | 356 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 3 | Systemic Treatment-naïve Pancreatic Cancer | 825 |
| AstraZeneca | Phase 3 | Lupus Nephritis | 363 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 246 |
| Pelage Pharmaceuticals, Inc. | Phase 3 | Androgenetic Alopecia | 600 |
| AbbVie | Phase 3 | Non-Segmental Vitiligo | 154 |
| Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Phase 3 | EGFR Activating Mutation; Non-Squamous Non-Small Cell Lung Cancer (NSCLC); MET Positive | 425 |
| Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Relapsed/Refractory Marginal Zone Lymphoma (MZL) | 292 |
| Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy | 480 |
| Celltrion | Phase 3 | Refractory or Relapsed Multiple Myeloma | 473 |
| Amgen | Phase 3 | Atherosclerotic Cardiovascular Disease | 7297 |
| Qilu Pharmaceutical Co., Ltd. | Phase 3 | Extrapulmonary Neuroendocrine Carcinoma | 270 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Non Small Cell Lung Cancer | 436 |
| Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Breast Cancer | 1050 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Non-squamous Non-small Cell Lung Cancer | 490 |
| Shionogi | Phase 3 | SARS-CoV-2 | 2000 |
| Multitude Therapeutics Inc. | Phase 3 | NSCLC (Advanced Non-small Cell Lung Cancer) | 512 |
| Hoffmann-La Roche | Phase 3 | Hepatocellular Carcinoma | 342 |
| Brise Pharmaceuticals Co., Ltd. | Phase 3 | Migraine, With or Without Aura | 2079 |
| AstraZeneca | Phase 3 | Unresectable Pleural Mesothelioma | 863 |
| Pfizer | Phase 3 | Stable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo | 1571 |
| Verrica Pharmaceuticals Inc. | Phase 3 | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Warts | 302 |
| Pfizer | Phase 3 | Ulcerative Colitis | 896 |
| Takeda | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 354 |
| Pfizer | Phase 3 | Early Breast Cancer; Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | 3800 |
| AVEO Pharmaceuticals, Inc. | Phase 3 | Cachexia; Cancer; Cachexia; Cachexia-Anorexia Syndrome; Metastatic Colorectal Cancer (CRC); Metastatic Non-small Cell Lung Cancer (NSCLC); Weight Loss | 950 |
| Hoffmann-La Roche | Phase 3 | Type 2 Diabetes Mellitus | 948 |
| Sanofi | Phase 3 | Immunization; Healthy Volunteers; COVID-19 Immunization; Influenza Immunization | 6000 |
| ScandiBio Therapeutics AB | Phase 3 | Gout Disease | 336 |
| Merck Sharp & Dohme LLC | Phase 3 | Papillomavirus Infections | 930 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 3 | Seasonal Allergic Rhinitis | 220 |
| AstraZeneca | Phase 3 | Breast Cancer; HER2-positive; Metastatic | 1157 |
| Merck Sharp & Dohme LLC | Phase 3 | Gastroesophageal Cancer | 473 |
| Alexion Pharmaceuticals, Inc. | Phase 3 | Transthyretin Amyloid Cardiomyopathy | 1182 |
| Hoffmann-La Roche | Phase 3 | Influenza, Human; Respiratory Tract Infections; Post-exposure Prophylaxis | 325 |
| Ultragenyx Pharmaceutical Inc | Phase 3 | Angelman Syndrome | 129 |
| Agios Pharmaceuticals, Inc. | Phase 3 | Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemia | 54 |
| MIBIO PTE. LTD. | Phase 3 | Thrombocytopenia Associated With Chronic Liver Disease | 150 |
| Enanta Pharmaceuticals, Inc | Phase 3 | RSV | 860 |
| Hoffmann-La Roche | Phase 3 | Non-Small Cell Lung Cancer | 68 |
| Janssen Research & Development, LLC | Phase 3 | Prostatic Neoplasms | 400 |
| Takeda | Phase 3 | Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy | 98 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 3 | First-line pMMR Endometrial Cancer | 333 |
| Jade Biosciences, Inc. | Phase 3 | IgA Nephropathy (IgAN) | 480 |
| argenx | Phase 3 | Generalized Myasthenia Gravis | 15 |
| AstraZeneca | Phase 3 | Asthma | 94 |
| Precigen, Inc | Phase 3 | Recurrent Respiratory Papillomatosis (RRP); Juvenile-onset Recurrent Respiratory Papillomatosis; Papillomavirus Infections | 15 |
| Laboratorios Silanes S.A. de C.V. | Phase 3 | Primary Dysmenorrhea | 130 |
| Amneal Pharmaceuticals, LLC | Phase 3 | Male Hypogonadism | 190 |
| Hanmi Pharmaceutical Company Limited | Phase 3 | Erectile Dysfunction | 225 |
| AstraZeneca | Phase 3 | Small Cell Lung Carcinoma | 71 |
| Debiopharm International SA | Phase 3 | Central Precocious Puberty | 56 |
| Albireo, an Ipsen Company | Phase 3 | Alagille Syndrome | 62 |
| Ipsen | Phase 3 | Primary Biliary Cholangitis | 18 |
| UroGen Pharma Ltd. | Phase 3 | Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder | 99 |
| Hellenic Institute for the Study of Sepsis | Phase 3 | Sepsis | 398 |
| Johns Hopkins University | Phase 3 | Alcohol Use Disorder (AUD); Withdrawal From Addictive Substance; Detoxification; Craving | 105 |
| Ultragenyx Pharmaceutical Inc | Phase 3 | Angelman Syndrome | 66 |
| VA Office of Research and Development | Phase 3 | Basal Cell Carcinoma | 1630 |
| Applied Biology, Inc. | Phase 3 | Androgenetic Alopecia; Female Pattern Baldness; Male Pattern Baldness | |
| Swiss Cancer Institute | Phase 3 | Metastatic NSCLC - Non-Small Cell Lung Cancer | 230 |
| University College, London | Phase 3 | Tuberculosis (TB) | 784 |
| Asian Institute of Gastroenterology, India | Phase 3 | Pancreatitis, Chronic; Exocrine Pancreatic Insufficiency (EPI) | 134 |
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | Allogeneic Stem Cell Transplantation; Lung Allograft Transplantation; Interstitial Lung Disease; Acute Lung Injury; Pulmonary Arterial Hypertension; Cardiovascular Diseases | 210 |
| Fujian Medical University Union Hospital | Phase 3 | Acute Ischemic Stroke; Large Vessel Occlusion | 1266 |
| Ruijin Hospital | Phase 3 | Non-Small-Cell Lung Cancer | 276 |
| Tata Memorial Hospital | Phase 3 | Gastroenteropancreatic Neuroendocrine Tumors | 123 |
| Ruijin Hospital | Phase 3 | Non-Small Cell Lung Cancer | 140 |
| First Affiliated Hospital of Wannan Medical College | Phase 3 | Ischemia Stroke; TIA (Transient Ischemic Attack) | 520 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | Tuberculosis, MDR | 5832 |
| University of Calgary | Phase 3 | Stroke, Acute Ischemic; Medium Vessel Occlusion | 800 |
| Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Phase 3 | Giant Cell Arteritis (GCA); Acute Coronary Syndrome (ACS); Ishemic and Thrombotic Complications | 120 |
| Beijing Ditan Hospital | Phase 3 | Neurosyphilis | 778 |
| Sun Yat-sen University | Phase 3 | Non-Clear Cell Renal Cell Carcinoma (nccRCC) | 108 |
| University of Utah | Phase 3 | HPV Vaccination; Uptake Vaccination; Series Completion | 1455 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 3 | Acute Ischemic Stroke | 826 |
| Ray Therapeutics, Inc. | Phase 3 | Retinitis Pigmentosa (RP); Inherited Retinal Diseases | 60 |
| Sir Run Run Shaw Hospital | Phase 3 | Rectal Cancer | 210 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 3 | Pneumocystis Jirovecii Pneumonia | 416 |
| University Hospital, Clermont-Ferrand | Phase 3 | Breast Cancer; Breast Surgery; Surgical Site Infection (SSI); Surgical Site Infection Prevention | 1600 |
| All India Institute of Medical Sciences | Phase 3 | Acute Ischemic Stroke | 440 |
| West China Hospital | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | 1088 |
| Capital Medical University | Phase 3 | Influenza, Human | 570 |
| Massachusetts General Hospital | Phase 3 | HIV (Human Immunodeficiency Virus); Cardiovascular Diseases (CVD); Arterial Inflammation; Heart Disease | 124 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Metastatic Breast Cancer (MBC); HER2-Positive Breast Cancer; Hormone Receptor-Positive Breast Cancer | 226 |
| NRG Oncology | Phase 3 | Advanced Head and Neck Squamous Cell Carcinoma; Advanced Hypopharyngeal Squamous Cell Carcinoma; Advanced Laryngeal Squamous Cell Carcinoma; Advanced Oropharyngeal Squamous Cell Carcinoma; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | 475 |
| SWOG Cancer Research Network | Phase 3 | Colorectal Neoplasms | 354 |
| Alliance for Clinical Trials in Oncology | Phase 3 | Multiple Myeloma (MM) | 920 |
| City of Hope Medical Center | Phase 3 | Hematopoietic and Lymphoid System Neoplasm | 113 |
| AstraZeneca | Phase 3 | Newly Diagnosed Multiple Myeloma (NDMM) | 750 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Generalized Anxiety Disorder | 1120 |
| Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Uncontrolled or Resistant Hypertension | 914 |
| Galderma R&D | Phase 3 | Atopic Dermatitis | 240 |
| AstraZeneca | Phase 3 | Platinum-sensitive Relapsed Epithelial Ovarian Cancer; Platinum-sensitive Relapsed Fallopian Tube Cancer; Platinum-sensitive Relapsed Primary Peritoneal Cancer | 600 |
| AstraZeneca | Phase 3 | Uncontrolled Hypertension | 286 |
| Pfizer | Phase 3 | Obesity | 180 |
| Pfizer | Phase 3 | Obesity; Overweight | 300 |
| AstraZeneca | Phase 3 | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 1330 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Atopic Dermatitis | 520 |
| GlaxoSmithKline | Phase 3 | Nasal Polyps | 218 |
| Minghui Pharmaceutical (Hangzhou) Ltd | Phase 3 | Thyroid Eye Disease, TED | 135 |
| BrightGene Bio-Medical Technology Co., Ltd. | Phase 3 | Type 2 Diabetes (T2DM) | 372 |
| Hoffmann-La Roche | Phase 3 | Non-small Cell Lung Cancer | 400 |
| Eli Lilly and Company | Phase 3 | Obesity | 150 |
| Pfizer | Phase 3 | Apnea; Sleep Disorders; Overweight and/or Obesity | 258 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Dermatitis, Atopic | 246 |
| Corbus Pharmaceuticals Inc. | Phase 3 | Oropharyngeal Carcinoma (OPC) | 260 |
| Phathom Pharmaceuticals, Inc. | Phase 3 | Symptomatic Non-erosive Gastroesophageal Reflux Disease | 500 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 3 | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | 362 |
| Novo Nordisk A/S | Phase 3 | Diabetes Mellitus, Type 2 | 210 |
| Akeso | Phase 3 | Gastric / Gastroesophageal Junction Adenocarcinoma | 900 |
| Novo Nordisk A/S | Phase 3 | Overweight; Obesity | 650 |
| Wake Forest University Health Sciences | Phase 3 | Obesity | 40 |
| Ohio State University | Phase 3 | Needle Phobia | 66 |
| Wockhardt | Phase 3 | Hospital Acquired Bacterial Pneumonia (HABP); Ventilator Associated Bacterial Pneumonia (VABP) | 324 |
| Kite, A Gilead Company | Phase 3 | Newly Diagnosed Multiple Myeloma | 600 |
| Pfizer | Phase 3 | Respiratory Syncytial Virus (RSV) | 750 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Chronic Myeloid Leukemia | 408 |
| Actinogen Medical | Phase 3 | Dementia Moderate; Dementia, Mild; Alzheimer Disease | 247 |
| Sanofi | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | 231 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 | Triple Negative Breast Cancer | 537 |
| Sanofi | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | 216 |
| AstraZeneca | Phase 3 | Breast Cancer | 1902 |
| Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Urothelial Carcinoma | 515 |
| GC Biopharma Corp | Phase 3 | Influenza A, Influenza B; Influenza Vaccination | 1806 |
| Biogen | Phase 3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | 158 |
| Merck Sharp & Dohme LLC | Phase 3 | Papillomavirus Infections | 6033 |
| Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 3 | Hypertriglyceridemia | 367 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Triple Negative Breast Cancer | 550 |
| Pfizer | Phase 3 | Apnea; Sleep Disorders; Overweight and/or Obesity | 258 |
| Eli Lilly and Company | Phase 3 | Obesity | 2115 |
| Eli Lilly and Company | Phase 3 | Obesity; Overweight; Diabetes Mellitus, Type 2 | 1000 |
| Ache Laboratorios Farmaceuticos S.A. | Phase 3 | Acute Pain | 370 |
| argenx | Phase 3 | Primary Immune Thrombocytopenia | 173 |
| AbbVie | Phase 3 | Non-Small Cell Lung Cancer | 167 |
| Day One Biopharmaceuticals, Inc. | Phase 3 | Low-grade Glioma; Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma; Pediatric Low-grade Glioma | 418 |
| Sanofi | Phase 3 | Meningococcal Infection; Healthy Volunteers | 1602 |
| AstraZeneca | Phase 3 | Gastric; Esophagogastric Junction | 140 |
| AbbVie | Phase 3 | Atopic Dermatitis | 184 |
All ClinicalTrialStartPulse record reports